Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2020 | Lung Cancer: post-frontline immunotherapy

Denis Talbot • 31 Jan 2020
BTOG 2020
Lung Cancer Non-Small Cell Lung Cancer

Denis Talbot, BSc, MB, BChir, MA, PhD, FRCP, University of Oxford, Oxford, UK, takes us through a study he co-authored assessing second-line real-world treatment patterns and outcomes in patients with advanced/metastatic non-small cell lung cancer treated with first-line immuno-oncology monotherapy. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

More from Denis Talbot

2:03
Early diagnosis: clinical implications
Denis Talbot • 30 Jan 2020
1:45
Neuroendocrine morphology
Denis Talbot • 30 Jan 2020
1:24
Denis Talbot: lifetime achievement award winner
Denis Talbot • 30 Jan 2020

Related Videos

2:38
Phase I trial of binimetinib and pembrolizumab in NSCLC
Natasha Leighl • 17 Apr 2024
2:43
CHRYSALIS: amivantamab in wild-type, pre-treated NSCLC
Natasha Leighl • 17 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals